Robeco Institutional Asset Management B.V. grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 23.5% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,371,169 shares of the biopharmaceutical company’s stock after purchasing an additional 261,074 shares during the quarter. Robeco Institutional Asset Management B.V. owned approximately 0.11% of Gilead Sciences worth $89,139,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in GILD. Athena Capital Advisors LLC purchased a new stake in Gilead Sciences in the 4th quarter worth approximately $27,000. Capital Financial Planning LLC purchased a new stake in Gilead Sciences in the 4th quarter worth approximately $27,000. Creative Financial Designs Inc. ADV increased its holdings in Gilead Sciences by 55.9% in the 1st quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 165 shares in the last quarter. Advisors Preferred LLC purchased a new stake in Gilead Sciences in the 4th quarter worth approximately $31,000. Finally, Legacy Financial Advisors Inc. increased its holdings in Gilead Sciences by 361.3% in the 4th quarter. Legacy Financial Advisors Inc. now owns 489 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 383 shares in the last quarter. 79.94% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts recently issued reports on the stock. Zacks Investment Research raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $69.00 target price for the company in a report on Tuesday, April 23rd. Mizuho set a $88.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research note on Friday, May 10th. BidaskClub upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Friday, May 3rd. ValuEngine upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday, May 1st. Finally, Cowen restated a “buy” rating on shares of Gilead Sciences in a research note on Friday, May 3rd. Nine investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Gilead Sciences has an average rating of “Buy” and a consensus target price of $81.61.
In related news, Director John Francis Cogan sold 2,700 shares of the firm’s stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $67.23, for a total value of $181,521.00. Following the completion of the sale, the director now directly owns 57,560 shares in the company, valued at $3,869,758.80. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Richard James Whitley sold 9,534 shares of the firm’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $65.48, for a total value of $624,286.32. Following the completion of the sale, the director now owns 34,669 shares of the company’s stock, valued at $2,270,126.12. The disclosure for this sale can be found here. Insiders have sold a total of 47,670 shares of company stock valued at $3,142,526 over the last quarter. Corporate insiders own 0.20% of the company’s stock.
NASDAQ GILD opened at $65.08 on Thursday. The company has a quick ratio of 3.53, a current ratio of 3.62 and a debt-to-equity ratio of 1.09. The company has a market cap of $81.81 billion, a PE ratio of 10.58, a PEG ratio of 0.78 and a beta of 1.14. Gilead Sciences, Inc. has a one year low of $60.32 and a one year high of $79.61.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.53 by $0.23. The firm had revenue of $5.28 billion during the quarter, compared to the consensus estimate of $5.29 billion. Gilead Sciences had a return on equity of 37.98% and a net margin of 26.40%. The company’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.48 EPS. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 6.6 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, June 13th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.87%. Gilead Sciences’s dividend payout ratio is currently 40.98%.
Gilead Sciences Profile
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
Read More: What is the 52-week high/low?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.